Medication info
Esprorole 20 mg (Esomeprazole Magnesium Trihydrate)

Esprorole 20 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›22.25mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets/box (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201403489 · Approved 2014.07.29 · Insurance code 649806670

Summary

Main use
Treatment of acid-related disorders (e.g., reflux); eradication therapy; treatment and prevention of ulcers, rebleeding, and drug-induced gastrointestinal disorders
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent episodes by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling ongoing symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Antibiotic combination therapy for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, and burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials extending beyond 4 weeks have not been conducted. 4) Patients requiring continuous administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: Dose adjustment is not required. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. 5. Hepatic impairment: Dose adjustment is not required in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this medicine. 6. Elderly patients: Dose adjustment is not required.
Children's dosage
2. Adolescents 12 years of age and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent episodes by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling ongoing symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age: There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of acid-related disorders (e.g., reflux); eradication therapy; treatment and prevention of ulcers, rebleeding, and drug-induced gastrointestinal disorders

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medicine is effective for long-term maintenance therapy to treat gastroesophageal reflux disease and prevent recurrence in patients with erosive esophagitis. It is also used to alleviate symptoms in patients with gastroesophageal reflux disease without esophagitis. It helps treat and prevent recurrence of peptic ulcers caused by Helicobacter pylori infection. It is applicable for treatment and prevention of symptoms or ulcers of the upper gastrointestinal tract caused by non-steroidal anti-inflammatory drugs. Lastly, it also contributes to stabilizing the patient's condition as maintenance therapy after preventing rebleeding from gastric ulcers or duodenal ulcers. Therefore, this medicine is widely used for the treatment and prevention of various gastrointestinal disorders.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water and must not be chewed or crushed. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent episodes by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling ongoing symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Antibiotic combination therapy for eradication of Helicobacter pylori Administer this medicine 20 mg in combination with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, and burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical trials extending beyond 4 weeks have not been conducted. 4) Patients requiring continuous administration of nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration Administer 40 mg once daily for 4 weeks following induction of prevention of rebleeding due to gastric or duodenal ulcers with intravenous administration. 4. Renal impairment: Dose adjustment is not required. Use with caution because there is limited experience administering this medicine to patients with severe renal impairment. 5. Hepatic impairment: Dose adjustment is not required in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed a dose of 20 mg of this medicine. 6. Elderly patients: Dose adjustment is not required.

Children's dosage

2. Adolescents 12 years of age and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, control subsequent episodes by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling ongoing symptoms in patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 3. Children under 12 years of age: There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. Patients with allergy to this drug or its components or who have experienced hypersensitivity to benzimidazoles should not use this drug. During Helicobacter pylori eradication therapy, patients allergic to penicillins or macrolide antibiotics should not use this drug in combination with amoxicillin or clarithromycin. Additionally, patients on certain heart-related medications or antivirals, and those with a history of myocardial infarction or breastfeeding should avoid this drug. Various adverse reactions may occur while taking this medicine, including headaches, abdominal pain, diarrhea, skin rash, muscle pain, etc. Rarely, serious blood abnormalities, hypersensitivity reactions, liver dysfunction, or severe skin reactions may occur, so immediate consultation with a healthcare professional is necessary if symptoms arise. Long-term use may require regular examinations, as there may be a slight increase in the risk of gastrointestinal infections. Electrolyte imbalances such as hypomagnesemia may also occur with prolonged use, so caution is needed. This drug has a high potential for drug interactions, so inform your doctor or pharmacist about any other medications you are taking. Particularly, caution is needed when combined with anticoagulants, antivirals, antibiotics, etc. During pregnancy, the safety of this drug has not been firmly established, so it should be used cautiously under the guidance of a physician, and it is advisable not to administer it while breastfeeding. In case of overdose, as there is no specific antidote, immediately go to a hospital for appropriate treatment. This medication should be stored out of reach of children and care should be taken not to transfer it to other containers.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic response, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, sensory disturbance, drowsiness, taste disorder, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, rigidity, peripheral edema, flushing, hypertension, tachycardia, goiter, irritable bowel syndrome, worsening of constipation, dyspepsia, dysphagia, gastrointestinal motility disorder, upper abdominal pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorder, pharyngeal disorder, rectal disorder, gastrointestinal symptoms, elevated serum gastrin, tongue disorder, tongue edema, ulcerative stomatitis, ear infection, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver dysfunction, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, worsening of arthritis, arthropathy, spasms, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, loss of appetite, apathy, increased appetite, confusion, worsening of depression, hypertonia, sensory loss, erectile dysfunction, insomnia, migraine, worsening of migraine, sleep disorders, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, worsening of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, anosmia, taste loss, taste disorder, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, micturition frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophagosthenosis, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets/box (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.